Lilly signs licensing deal with Mediar for IPF drug
[ad_1]
Lilly signs licensing deal with Mediar for IPF drug
[ad_2]
[ad_1] Greenbrier Q1 2025 Earnings Preview [ad_2]
[ad_1] Context Therapeutics names Andy Pasternak as chair [ad_2]
[ad_1] Life Time Group expects Q4 revenue between $661M and $663M, shares up over 6% [ad_2]
[ad_1] You jolt awake and instantly know something is wrong. Your head is pounding, your stomach is churning, and your body feels like lead. As you glance at the clock through bleary eyes, your heart sinks. It’s 7 AM…time to start getting ready for work. There’s no way you can drag yourself to the office…
[ad_1] United States Antimony files for $100M mixed securities shelf [ad_2]
[ad_1] Incyte, Syndax get FDA okay for 9 mg, 22 mg Niktimvo vials [ad_2]